TOQQ-RCC
Using Tele-mentoring to Optimize Quality of Care and Quality of Life for Patients with Metastatic Kidney Cancer

Co-Primary Investigator: Elizabeth Wulff-Burchfield, MD
Co-Primary Investigator: Jennifer Klemp, PhD
Project Funding: Pfizer Medical Education Grant

RCC_Kidneys.png

Project Goal
The goal for this project was to use tele-mentoring to improve existing knowledge deficits and clinical care gaps regarding symptom and toxicity assessment and management for patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitor (ICI) and/or tyrosine kinase inhibitor (TKI) therapy treated in rural or community oncology settings.   

1200px-Circle-icons-toolbox.svg.png

TOQQ-RCC Toolbox

Materials from the Project ECHO® learning sessions.

All case studies are fictional patients and for educational purposes only. 

Session 1
April 16, 2021

Baseline Patient Assessment, Distress Screening, Renal Cell Carcinoma (RCC) Treatment Decision-Making
Guest Speaker: Jessica Hamilton, PhD

Session 2
May 14, 2021

Cytoreductive Nephrectomy in the CARMENA Era, Shared Decision-Making for Medical and Surgical RCC Treatment
Guest Speaker: Eugene Lee, MD

Session 3
June 11, 2021

Immunotherapy Toxicity Monitoring and Management, At-Home Immunotherapy Administration
Guest Speaker: Gary Doolittle, MD

Session 4
July 16, 2021

Tyrosine Kinase Inhibitor (TKI) Toxicity Monitoring and Management
Guest Speaker: Grace Martin, PharmD

Session 5
August 13, 2021

Toxicity Education, Monitoring and Management Regarding Combination Immunotherapy or TKI-Immunotherapy Regimens for RCC
Guest Speaker: Jennifer Heins, PA